2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

1946 Impact of frailty on outcomes of patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies

Sirui Ma, MD, Rebecca L Olin, MD2, Weiyun Ai, MD, PhD3, Charalambos Andreadis, MD, MS4, Carrie Ho, MD5, Lawrence Kaplan, MD6, Mwanasha Merrill, MD7, Michael Paul Randall, MD8, Madhav Seshadri, MD9, Michael Alexander Spinner, MD10
1 University of California, San Francisco, San Francisco, California, United States
2 University of California, San Francisco, San Francisco, California, United States
3 University of California, San Francisco, San Francisco, California, United States
4 University of California, San Francisco, San Francisco, California, United States
5 University of California, San Francisco, San Francisco, California, United States
6 University of California, San Francisco, San Francisco, California, United States
7 University of California, San Francisco, San Francisco, California, United States
8 University of California, San Francisco, San Francisco, California, United States
9 University of California, San Francisco, San Francisco, California, United States
10 University of California, San Francisco, San Francisco, California, United States

Introduction: Bispecific antibodies (BsAbs) targeting CD3xCD20 have emerged as highly effective agents in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), with particular appeal in older or less fit patients ineligible for high-dose chemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy. Frailty, defined by validated assessment tools, is an increasingly recognized predictor of treatment tolerability and survival in LBCL, but its impact on outcomes with BsAbs remains poorly characterized.

Methods: We performed a single-center retrospective study of patients with R/R LBCL treated with epcoritamab, glofitamab, or mosunetuzumab as monotherapy or in combination with chemotherapy at the University of California, San Francisco between January 2022 and March 2026. Patient frailty was assessed from clinical documentation within 3 months of BsAb initiation. We defined frailty using prespecified measures including ECOG performance status (PS), Cumulative Illness Rating Scale-Geriatric (CIRS-G), and activities of daily living (ADL) and instrumental ADL (IADL) impairment. The simplified geriatric assessment (sGA) frailty category (fit, unfit, or frail) was determined for patients with available clinical information. The primary endpoint was overall survival (OS), and secondary endpoints included overall response rate (ORR), complete response rate (CRR), progression-free survival (PFS), non-relapse mortality (NRM), and treatment-related toxicities, delays, and discontinuation. Survival times were estimated by the Kaplan-Meier method and compared using the log-rank test.

Results: The study comprised 66 patients with a median age of 74 years (IQR 64-79). Most patients had advanced stage disease (84.9%) and international prognostic index ≥3 (74.3%) at diagnosis, with a median of 2 prior lines of therapy. Most patients received glofitamab (65.2%), followed by epcoritamab (21.2%) and mosunetuzumab (13.6%). Seventeen (25.8%) patients received BsAb combinations, most commonly glofitamab with gemcitabine and oxaliplatin in 7 patients. The proportion receiving concurrent chemotherapy did not differ significantly between frail and non-frail patients across all frailty instruments (range 20.7–46.7% vs. 24.0–29.7%; all p>0.05). The ORR and CRR were 59.1% and 40.9%, respectively. With a median follow-up of 13.6 months, median PFS and OS were 4.6 and 11.8 months, respectively, with 1-year PFS and OS of 33.0% and 49.7%, respectively. Four non-relapse deaths occurred with 1-year NRM of 4.0%.

Frailty measures were consistently associated with inferior outcomes. Patients with ECOG PS ≥2 were older (median age 77.0 vs 67.0 years, p=0.004) and had shorter median OS (4.1 vs 16.4 months, p=0.03) compared to those with ECOG PS <2. High comorbidity burden (CIRS-G score ≥10) was associated with lower ORR (32.0% vs 75.6%, p=0.001), CRR (24.0% vs 51.2%, p=0.04), median PFS (2.0 vs 8.8 months, p=0.0004), and median OS (3.3 vs 22.2 months, p=0.001), as well as higher rates of infection (80.0% vs 46.3%, p=0.01), grade 3-4 hematotoxicity (68.0% vs 41.5%, p=0.045), and a numerically higher rate of treatment discontinuation (20.0% vs 7.3%, p=0.24). Baseline ADL impairment was associated with numerically higher rates of treatment delays (53.3% vs 25.5%, p=0.059) and discontinuation (26.7% vs 7.8%, p=0.071). Among patients evaluable by sGA (n=48), fit patients had longer median OS (not reached [NR] vs 5.6 vs 6.2 months, p=0.01) and lower rates of infection (25.0% vs 71.4% vs 60.0%, p=0.03) and treatment delay (8.3% vs 52.4% vs 26.7%, p=0.028) compared to unfit and frail patients, respectively. In sensitivity analysis restricted to BsAb monotherapy recipients (n=49), statistically significant associations between frailty and inferior median OS were preserved across CIRS-G (17.0 vs. 3.4 months, p=0.012) and sGA instruments (NR vs 5.7 vs 4.4 months, p=0.032).

Conclusions: Among patients with R/R LBCL treated with BsAbs, frailty as determined by conventional clinical measures and validated assessment tools was associated with inferior survival, potentially driven by higher rates of treatment-related toxicity, delays, and discontinuation. Though limited by the retrospective design and potential confounding between frailty status and disease burden, these findings support routine pre-treatment assessment of patient frailty and frailty-stratified analyses in clinical trials to guide treatment selection and optimize supportive care strategies.

Sirui Ma, MD: No relevant conflicts of interest to declare.